Natural Product: NPC44830
Natural Product ID:   | NPC44830 |
Common Name*:   | 12-Phenyldodecanoic Acid |
IUPAC Name:   | 12-phenyldodecanoic acid |
Synonyms:   | |
Standard InCHIKey:   | IXEHFJJSVBVZHI-UHFFFAOYSA-N |
Standard InCHI:   | InChI=1S/C18H28O2/c19-18(20)16-12-7-5-3-1-2-4-6-9-13-17-14-10-8-11-15-17/h8,10-11,14-15H,1-7,9,12-13,16H2,(H,19,20) |
SMILES:   | OC(=O)CCCCCCCCCCCc1ccccc1
|
Synthetic Gene Cluster:   |
n.a. |
ChEMBL Identifier:   |
CHEMBL1567811 |
PubChem CID:   |
151922 |
Chemical Classification**:   |
-
CHEMONTID:0000000 [Organic compounds]
-
[CHEMONTID:0000012] Lipids and lipid-like molecules
-
[CHEMONTID:0003909] Fatty Acyls
[CHEMONTID:0000262] Fatty acids and conjugates[CHEMONTID:0002949] Long-chain fatty acids
|
*Note: the InCHIKey will be temporarily assigned as the "Common Name" if no IUPAC name or alternative short name is available.
**Note: the Chemical Classification was calculated by NPClassifier Version 1.5. Reference: PMID:34662515.
  Species Source
Organism ID |
Organism Name |
Taxonomy Level |
Family |
SuperKingdom |
Isolation Part |
Collection Location |
Collection Time |
Reference |
NPO16657 |
Diospyros maritima |
Species |
Ebenaceae |
Eukaryota |
bark |
Indonesia |
n.a. |
PMID[15270571] |
NPO21076 |
Nephthea armata |
Species |
Nephtheidae |
Eukaryota |
n.a. |
Taiwan |
n.a. |
PMID[15387641] |
NPO22180 |
Dracaena mannii |
Species |
Asparagaceae |
Eukaryota |
n.a. |
stem |
n.a. |
PMID[18481024] |
NPO22180 |
Dracaena mannii |
Species |
Asparagaceae |
Eukaryota |
stems |
Yaound, village of Bangoua, near Bangangt |
2007-APR |
PMID[20553003] |
NPO16657 |
Diospyros maritima |
Species |
Ebenaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
PMID[22313254] |
NPO5386 |
Citrus paradisi |
Species |
Rutaceae |
Eukaryota |
|
n.a. |
n.a. |
Database[FooDB] |
NPO5386 |
Citrus paradisi |
Species |
Rutaceae |
Eukaryota |
n.a. |
n.a. |
|
Database[FooDB] |
NPO16657 |
Diospyros maritima |
Species |
Ebenaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[HerDing] |
NPO5386 |
Citrus paradisi |
Species |
Rutaceae |
Eukaryota |
Fruits |
n.a. |
|
Database[Phenol-Explorer] |
NPO5386 |
Citrus paradisi |
Species |
Rutaceae |
Eukaryota |
n.a. |
n.a. |
|
Database[Phenol-Explorer] |
NPO5386 |
Citrus paradisi |
Species |
Rutaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TCMID] |
NPO19432 |
Millettia pinnata |
Species |
Fabaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TCMID] |
NPO16657 |
Diospyros maritima |
Species |
Ebenaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TCMID] |
NPO16657 |
Diospyros maritima |
Species |
Ebenaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[TCM_Taiwan] |
NPO5386 |
Citrus paradisi |
Species |
Rutaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO20571 |
Limnodynastes interioris |
Species |
Myobatrachidae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO16657 |
Diospyros maritima |
Species |
Ebenaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO22180 |
Dracaena mannii |
Species |
Asparagaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO19432 |
Millettia pinnata |
Species |
Fabaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO22064 |
Mannia fragrans |
Species |
Aytoniaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO18284 |
Cytisus ciliatus |
Species |
Fabaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO20708 |
Mesua beccariana |
Species |
Calophyllaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO21076 |
Nephthea armata |
Species |
Nephtheidae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO22867 |
Stephanitis rhododendri |
Species |
Tingidae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO22525 |
Lobophytum denticulatum |
Species |
Alcyoniidae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO22923 |
Parthenium bipinnatifidum |
Species |
Asteraceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO19330 |
Cephalaria procera |
Species |
Caprifoliaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO22007 |
Acer spicatum |
Species |
Sapindaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO21819 |
Domohinea perrieri |
Species |
Euphorbiaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO22125 |
Helipterum propinquum |
Species |
Asteraceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO29112 |
Streptomyces luteosporeus |
Species |
Streptomycetaceae |
Bacteria |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
NPO17813 |
Pittosporum undulatum |
Species |
Pittosporaceae |
Eukaryota |
n.a. |
n.a. |
n.a. |
Database[UNPD] |
☑ Note for Reference:
In addition to directly collecting NP source organism data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated them from below databases:
☉ UNPD: Universal Natural Products Database [PMID: 23638153].
☉ StreptomeDB: a database of streptomycetes natural products [PMID: 33051671].
☉ TM-MC: a database of medicinal materials and chemical compounds in Northeast Asian traditional medicine [PMID: 26156871].
☉ TCM@Taiwan: a Traditional Chinese Medicine database [PMID: 21253603].
☉ TCMID: a Traditional Chinese Medicine database [PMID: 29106634].
☉ TCMSP: The traditional Chinese medicine systems pharmacology database and analysis platform [PMID: 24735618].
☉ HerDing: a herb recommendation system to treat diseases using genes and chemicals [PMID: 26980517].
☉ MetaboLights: a metabolomics database [PMID: 27010336].
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
  NP Quantity Composition/Concentration
Organism ID |
NP ID |
Organism Material Preparation |
Organism Part |
NP Quantity (Standard) |
NP Quantity (Minimum) |
NP Quantity (Maximum) |
Quantity Unit |
Reference |
☑ Note for Reference:
In addition to directly collecting NP quantitative data from primary literature (where reference will provided as NCBI PMID or DOI links), NPASS also integrated NP quantitative records for specific NP domains (e.g., NPS from foods or herbs) from domain-specific databases. These databases include:
☉ DUKE: Dr. Duke's Phytochemical and Ethnobotanical Databases.
☉ PHENOL EXPLORER: is the first comprehensive database on polyphenol content in foods [PMID: 24103452], its homepage can be accessed at here.
☉ FooDB: a database of constituents, chemistry and biology of food species [www.foodb.ca].
  Biological Activity
Activity Type |
# Activity |
IC50 |
2 |
Potency |
14 |
Activity Type |
# Activity |
Individual Protein |
13 |
Organism |
2 |
Protein-Protein Interaction |
1 |
Target ID |
Target Type |
Target Name |
Target Organism |
Activity Type |
Activity Relation |
Value |
Unit |
Reference |
NPT51 |
Individual Protein |
Microtubule-associated protein tau |
Homo sapiens |
Potency |
= |
15848.9 |
nM |
PMID[515538] |
NPT442 |
Individual Protein |
Ferritin light chain |
Equus caballus |
Potency |
= |
14125.4 |
nM |
PMID[515538] |
NPT55 |
Individual Protein |
Putative fructose-1,6-bisphosphate aldolase |
Giardia intestinalis |
Potency |
= |
15811.4 |
nM |
PMID[515538] |
NPT56 |
Individual Protein |
Beta-lactamase AmpC |
Escherichia coli K-12 |
Potency |
= |
28183.8 |
nM |
PMID[515538] |
NPT2944 |
Individual Protein |
Relaxin receptor 1 |
Homo sapiens |
Potency |
= |
35481.3 |
nM |
PMID[515538] |
NPT443 |
Individual Protein |
Histone acetyltransferase GCN5 |
Homo sapiens |
Potency |
n.a. |
39810.7 |
nM |
PMID[515538] |
NPT5 |
Individual Protein |
Histone-lysine N-methyltransferase, H3 lysine-9 specific 3 |
Homo sapiens |
Potency |
n.a. |
398.1 |
nM |
PMID[515538] |
NPT63 |
Individual Protein |
Bromodomain adjacent to zinc finger domain protein 2B |
Homo sapiens |
Potency |
n.a. |
100000.0 |
nM |
PMID[515538] |
NPT484 |
Individual Protein |
Luciferin 4-monooxygenase |
Photinus pyralis |
Potency |
n.a. |
23934.1 |
nM |
PMID[515538] |
NPT1255 |
Individual Protein |
Sentrin-specific protease 8 |
Homo sapiens |
IC50 |
n.a. |
100000.0 |
nM |
PMID[515538] |
NPT161 |
Individual Protein |
Rap guanine nucleotide exchange factor 4 |
Homo sapiens |
Potency |
n.a. |
56234.1 |
nM |
PMID[515538] |
NPT533 |
Protein-Protein Interaction |
Runt-related transcription factor 1/Core-binding factor subunit beta |
Homo sapiens |
Potency |
n.a. |
22387.2 |
nM |
PMID[515538] |
NPT6 |
Organism |
Plasmodium falciparum |
Plasmodium falciparum |
Potency |
n.a. |
11689.1 |
nM |
PMID[515538] |
NPT6 |
Organism |
Plasmodium falciparum |
Plasmodium falciparum |
Potency |
n.a. |
369.6 |
nM |
PMID[515538] |
NPT831 |
Individual Protein |
Serine/threonine-protein kinase PLK1 |
Homo sapiens |
Potency |
n.a. |
23778.1 |
nM |
PMID[515538] |
☑ Note for Activity Records:
☉ The quantitative biological activities were primarily integrated from ChEMBL (Version-30) database and were also directly collected from PubMed literature. PubMed PMID was provided as the reference link for each activity record.
  Chemically structural similarity: I. Similar Active Natural Products in NPASS
Top-200 similar NPs were calculated against the active-NP-set (includes 4,3285 NPs with experimentally-derived bioactivity available in NPASS)
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules. Tc lies between [0, 1] where '1' indicates the highest similarity. What is Tanimoto coefficient
●  The left chart: Distribution of similarity level between NPC44830 and all remaining natural products in the NPASS database.
●  The right table: Most similar natural products (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 173 |
0.1-0.2 | 910 |
0.2-0.3 | 3254 |
0.3-0.4 | 12219 |
0.4-0.5 | 17642 |
0.5-0.6 | 6802 |
0.6-0.7 | 1364 |
0.7-0.8 | 287 |
0.8-0.85 | 33 |
0.85-0.9 | 9 |
0.9-0.95 | 2 |
0.95-1 | 2 |
  Chemically structural similarity: II. Similar Clinical/Approved Drugs
Similarity level is defined by Tanimoto coefficient (Tc) between two molecules.
●  The left chart: Distribution of similarity level between NPC44830 and all drugs/candidates.
●  The right table: Most similar clinical/approved drugs (Tc>=0.56 or Top200).
range |
Tanimoto Coefficient |
0-0.1 | 165 |
0.1-0.2 | 797 |
0.2-0.3 | 1498 |
0.3-0.4 | 3082 |
0.4-0.5 | 2205 |
0.5-0.6 | 1038 |
0.6-0.7 | 286 |
0.7-0.8 | 52 |
0.8-0.85 | 13 |
0.85-0.9 | 6 |
0.9-0.95 | 6 |
0.95-1 | 2 |
Similarity Score |
Similarity Level |
Drug ID |
Developmental Stage |
0.9506 |
High Similarity |
NPD4793 |
Discontinued |
0.9487 |
High Similarity |
NPD226 |
Approved |
0.9277 |
High Similarity |
NPD5346 |
Phase 2 |
0.9277 |
High Similarity |
NPD5347 |
Phase 2 |
0.925 |
High Similarity |
NPD9491 |
Approved |
0.9103 |
High Similarity |
NPD227 |
Approved |
0.9103 |
High Similarity |
NPD225 |
Approved |
0.9048 |
High Similarity |
NPD800 |
Approved |
0.8941 |
High Similarity |
NPD1089 |
Approved |
0.8941 |
High Similarity |
NPD1086 |
Approved |
0.8941 |
High Similarity |
NPD1090 |
Approved |
0.8851 |
High Similarity |
NPD5122 |
Clinical (unspecified phase) |
0.875 |
High Similarity |
NPD9490 |
Approved |
0.8736 |
High Similarity |
NPD1088 |
Approved |
0.8621 |
High Similarity |
NPD1239 |
Approved |
0.8588 |
High Similarity |
NPD1087 |
Approved |
0.8539 |
High Similarity |
NPD1693 |
Approved |
0.8506 |
High Similarity |
NPD3673 |
Approved |
0.8506 |
High Similarity |
NPD3672 |
Approved |
0.8444 |
Intermediate Similarity |
NPD5206 |
Clinical (unspecified phase) |
0.837 |
Intermediate Similarity |
NPD2066 |
Phase 3 |
0.837 |
Intermediate Similarity |
NPD3097 |
Clinical (unspecified phase) |
0.8333 |
Intermediate Similarity |
NPD688 |
Clinical (unspecified phase) |
0.8152 |
Intermediate Similarity |
NPD1566 |
Phase 3 |
0.8152 |
Intermediate Similarity |
NPD1564 |
Approved |
0.8152 |
Intermediate Similarity |
NPD1565 |
Approved |
0.8065 |
Intermediate Similarity |
NPD253 |
Approved |
0.8043 |
Intermediate Similarity |
NPD1989 |
Approved |
0.8 |
Intermediate Similarity |
NPD1932 |
Approved |
0.7957 |
Intermediate Similarity |
NPD9566 |
Approved |
0.7917 |
Intermediate Similarity |
NPD1930 |
Approved |
0.7917 |
Intermediate Similarity |
NPD1931 |
Clinical (unspecified phase) |
0.7917 |
Intermediate Similarity |
NPD1929 |
Approved |
0.7889 |
Intermediate Similarity |
NPD9256 |
Approved |
0.7889 |
Intermediate Similarity |
NPD9258 |
Approved |
0.7872 |
Intermediate Similarity |
NPD9495 |
Approved |
0.7835 |
Intermediate Similarity |
NPD5909 |
Discontinued |
0.7826 |
Intermediate Similarity |
NPD1563 |
Approved |
0.7826 |
Intermediate Similarity |
NPD1066 |
Discontinued |
0.7732 |
Intermediate Similarity |
NPD5765 |
Approved |
0.77 |
Intermediate Similarity |
NPD6831 |
Clinical (unspecified phase) |
0.764 |
Intermediate Similarity |
NPD9257 |
Approved |
0.764 |
Intermediate Similarity |
NPD9259 |
Approved |
0.7624 |
Intermediate Similarity |
NPD5278 |
Discontinued |
0.7604 |
Intermediate Similarity |
NPD7798 |
Approved |
0.759 |
Intermediate Similarity |
NPD9716 |
Approved |
0.7576 |
Intermediate Similarity |
NPD5048 |
Discontinued |
0.7551 |
Intermediate Similarity |
NPD5738 |
Clinical (unspecified phase) |
0.7551 |
Intermediate Similarity |
NPD6647 |
Phase 2 |
0.7549 |
Intermediate Similarity |
NPD3643 |
Approved |
0.7549 |
Intermediate Similarity |
NPD3644 |
Approved |
0.7549 |
Intermediate Similarity |
NPD3642 |
Approved |
0.7528 |
Intermediate Similarity |
NPD5734 |
Clinical (unspecified phase) |
0.7525 |
Intermediate Similarity |
NPD2329 |
Discontinued |
0.75 |
Intermediate Similarity |
NPD3971 |
Phase 1 |
0.75 |
Intermediate Similarity |
NPD6685 |
Approved |
0.75 |
Intermediate Similarity |
NPD467 |
Phase 1 |
0.7451 |
Intermediate Similarity |
NPD1317 |
Discontinued |
0.7447 |
Intermediate Similarity |
NPD1202 |
Approved |
0.7423 |
Intermediate Similarity |
NPD1067 |
Discontinued |
0.7356 |
Intermediate Similarity |
NPD1507 |
Clinical (unspecified phase) |
0.7333 |
Intermediate Similarity |
NPD3598 |
Phase 3 |
0.7333 |
Intermediate Similarity |
NPD2650 |
Approved |
0.7333 |
Intermediate Similarity |
NPD2652 |
Approved |
0.7273 |
Intermediate Similarity |
NPD942 |
Approved |
0.7264 |
Intermediate Similarity |
NPD5951 |
Approved |
0.7264 |
Intermediate Similarity |
NPD2629 |
Approved |
0.7212 |
Intermediate Similarity |
NPD189 |
Phase 3 |
0.7212 |
Intermediate Similarity |
NPD188 |
Approved |
0.7143 |
Intermediate Similarity |
NPD6912 |
Phase 3 |
0.713 |
Intermediate Similarity |
NPD5162 |
Approved |
0.7129 |
Intermediate Similarity |
NPD1237 |
Approved |
0.7115 |
Intermediate Similarity |
NPD4234 |
Approved |
0.7115 |
Intermediate Similarity |
NPD3646 |
Clinical (unspecified phase) |
0.7115 |
Intermediate Similarity |
NPD4233 |
Approved |
0.7115 |
Intermediate Similarity |
NPD2067 |
Discontinued |
0.7097 |
Intermediate Similarity |
NPD1101 |
Approved |
0.7075 |
Intermediate Similarity |
NPD5277 |
Phase 2 |
0.7071 |
Intermediate Similarity |
NPD1238 |
Approved |
0.7059 |
Intermediate Similarity |
NPD1018 |
Approved |
0.7059 |
Intermediate Similarity |
NPD1040 |
Phase 2 |
0.7053 |
Intermediate Similarity |
NPD7609 |
Phase 3 |
0.7048 |
Intermediate Similarity |
NPD2181 |
Clinical (unspecified phase) |
0.7048 |
Intermediate Similarity |
NPD4141 |
Clinical (unspecified phase) |
0.7019 |
Intermediate Similarity |
NPD476 |
Approved |
0.7019 |
Intermediate Similarity |
NPD2182 |
Approved |
0.7011 |
Intermediate Similarity |
NPD9294 |
Approved |
0.701 |
Intermediate Similarity |
NPD9260 |
Approved |
0.7009 |
Intermediate Similarity |
NPD1280 |
Clinical (unspecified phase) |
0.7009 |
Intermediate Similarity |
NPD6010 |
Discontinued |
0.6979 |
Remote Similarity |
NPD7631 |
Approved |
0.6972 |
Remote Similarity |
NPD3797 |
Approved |
0.697 |
Remote Similarity |
NPD5926 |
Approved |
0.6961 |
Remote Similarity |
NPD164 |
Approved |
0.6952 |
Remote Similarity |
NPD1752 |
Approved |
0.6952 |
Remote Similarity |
NPD1756 |
Approved |
0.6944 |
Remote Similarity |
NPD747 |
Discontinued |
0.6944 |
Remote Similarity |
NPD1246 |
Approved |
0.6937 |
Remote Similarity |
NPD6993 |
Approved |
0.6937 |
Remote Similarity |
NPD4105 |
Approved |
0.6937 |
Remote Similarity |
NPD4102 |
Approved |
0.6937 |
Remote Similarity |
NPD6994 |
Approved |
0.6937 |
Remote Similarity |
NPD5981 |
Approved |
0.6916 |
Remote Similarity |
NPD7094 |
Approved |
0.6916 |
Remote Similarity |
NPD181 |
Approved |
0.6916 |
Remote Similarity |
NPD2607 |
Approved |
0.6916 |
Remote Similarity |
NPD6858 |
Approved |
0.6915 |
Remote Similarity |
NPD531 |
Approved |
0.6907 |
Remote Similarity |
NPD3718 |
Approved |
0.6907 |
Remote Similarity |
NPD3719 |
Approved |
0.6887 |
Remote Similarity |
NPD5927 |
Discontinued |
0.6881 |
Remote Similarity |
NPD255 |
Approved |
0.6881 |
Remote Similarity |
NPD1348 |
Approved |
0.6881 |
Remote Similarity |
NPD256 |
Approved |
0.6875 |
Remote Similarity |
NPD7163 |
Clinical (unspecified phase) |
0.6875 |
Remote Similarity |
NPD5306 |
Approved |
0.6875 |
Remote Similarity |
NPD5305 |
Approved |
0.6852 |
Remote Similarity |
NPD1681 |
Approved |
0.6852 |
Remote Similarity |
NPD1682 |
Approved |
0.6852 |
Remote Similarity |
NPD1680 |
Approved |
0.6847 |
Remote Similarity |
NPD3798 |
Phase 3 |
0.6847 |
Remote Similarity |
NPD2617 |
Discontinued |
0.6837 |
Remote Similarity |
NPD4814 |
Discontinued |
0.6837 |
Remote Similarity |
NPD6048 |
Clinical (unspecified phase) |
0.6837 |
Remote Similarity |
NPD6049 |
Phase 2 |
0.6832 |
Remote Similarity |
NPD3135 |
Clinical (unspecified phase) |
0.6822 |
Remote Similarity |
NPD9508 |
Approved |
0.6814 |
Remote Similarity |
NPD3881 |
Discontinued |
0.6814 |
Remote Similarity |
NPD4135 |
Approved |
0.6814 |
Remote Similarity |
NPD4106 |
Approved |
0.6814 |
Remote Similarity |
NPD4136 |
Approved |
0.6809 |
Remote Similarity |
NPD9538 |
Approved |
0.6809 |
Remote Similarity |
NPD650 |
Approved |
0.6789 |
Remote Similarity |
NPD690 |
Clinical (unspecified phase) |
0.6789 |
Remote Similarity |
NPD4766 |
Approved |
0.6786 |
Remote Similarity |
NPD4504 |
Clinical (unspecified phase) |
0.6786 |
Remote Similarity |
NPD1855 |
Clinical (unspecified phase) |
0.6768 |
Remote Similarity |
NPD2860 |
Approved |
0.6768 |
Remote Similarity |
NPD2859 |
Approved |
0.6762 |
Remote Similarity |
NPD9265 |
Clinical (unspecified phase) |
0.6762 |
Remote Similarity |
NPD9267 |
Approved |
0.6762 |
Remote Similarity |
NPD9264 |
Approved |
0.6762 |
Remote Similarity |
NPD9263 |
Approved |
0.6757 |
Remote Similarity |
NPD1758 |
Phase 1 |
0.6754 |
Remote Similarity |
NPD3603 |
Phase 3 |
0.6754 |
Remote Similarity |
NPD3131 |
Approved |
0.6754 |
Remote Similarity |
NPD4807 |
Approved |
0.6754 |
Remote Similarity |
NPD3132 |
Approved |
0.6754 |
Remote Similarity |
NPD4215 |
Approved |
0.6754 |
Remote Similarity |
NPD2608 |
Approved |
0.6754 |
Remote Similarity |
NPD2610 |
Approved |
0.6754 |
Remote Similarity |
NPD4217 |
Approved |
0.6754 |
Remote Similarity |
NPD2611 |
Approved |
0.6754 |
Remote Similarity |
NPD4218 |
Approved |
0.6754 |
Remote Similarity |
NPD4806 |
Approved |
0.6754 |
Remote Similarity |
NPD4216 |
Approved |
0.6754 |
Remote Similarity |
NPD2612 |
Approved |
0.6754 |
Remote Similarity |
NPD2609 |
Approved |
0.6735 |
Remote Similarity |
NPD719 |
Approved |
0.6735 |
Remote Similarity |
NPD720 |
Approved |
0.6735 |
Remote Similarity |
NPD1409 |
Phase 3 |
0.6733 |
Remote Similarity |
NPD9712 |
Approved |
0.6726 |
Remote Similarity |
NPD2345 |
Approved |
0.6726 |
Remote Similarity |
NPD4199 |
Phase 3 |
0.6701 |
Remote Similarity |
NPD530 |
Approved |
0.67 |
Remote Similarity |
NPD1875 |
Phase 1 |
0.67 |
Remote Similarity |
NPD3495 |
Discontinued |
0.6698 |
Remote Similarity |
NPD74 |
Approved |
0.6698 |
Remote Similarity |
NPD9266 |
Approved |
0.6697 |
Remote Similarity |
NPD1370 |
Approved |
0.6697 |
Remote Similarity |
NPD1374 |
Approved |
0.6697 |
Remote Similarity |
NPD1371 |
Approved |
0.6697 |
Remote Similarity |
NPD1373 |
Approved |
0.6696 |
Remote Similarity |
NPD4479 |
Discontinued |
0.6696 |
Remote Similarity |
NPD3880 |
Clinical (unspecified phase) |
0.6696 |
Remote Similarity |
NPD1894 |
Discontinued |
0.6696 |
Remote Similarity |
NPD1759 |
Phase 1 |
0.6667 |
Remote Similarity |
NPD4576 |
Approved |
0.6667 |
Remote Similarity |
NPD9568 |
Approved |
0.6667 |
Remote Similarity |
NPD4574 |
Approved |
0.6667 |
Remote Similarity |
NPD2933 |
Approved |
0.6667 |
Remote Similarity |
NPD4094 |
Approved |
0.6667 |
Remote Similarity |
NPD689 |
Discontinued |
0.6667 |
Remote Similarity |
NPD2934 |
Approved |
0.6637 |
Remote Similarity |
NPD1245 |
Approved |
0.6634 |
Remote Similarity |
NPD9710 |
Approved |
0.6634 |
Remote Similarity |
NPD9711 |
Approved |
0.6633 |
Remote Similarity |
NPD752 |
Approved |
0.6633 |
Remote Similarity |
NPD1508 |
Approved |
0.6633 |
Remote Similarity |
NPD6690 |
Approved |
0.6632 |
Remote Similarity |
NPD506 |
Clinical (unspecified phase) |
0.6609 |
Remote Similarity |
NPD4761 |
Approved |
0.6609 |
Remote Similarity |
NPD4762 |
Approved |
0.6609 |
Remote Similarity |
NPD4706 |
Clinical (unspecified phase) |
0.6607 |
Remote Similarity |
NPD7610 |
Discontinued |
0.6607 |
Remote Similarity |
NPD2116 |
Approved |
0.6607 |
Remote Similarity |
NPD2115 |
Approved |
0.6607 |
Remote Similarity |
NPD2117 |
Pre-registration |
0.6607 |
Remote Similarity |
NPD6065 |
Approved |
0.6606
|
Remote Similarity |
NPD1279 |
Clinical (unspecified phase) |